CSLS Revenue and Competitors
Estimated Revenue & Valuation
- CSLS's estimated annual revenue is currently $3.9B per year.
- CSLS's estimated revenue per employee is $155,000
Employee Data
- CSLS has 25475 Employees.
- CSLS grew their employee count by 4% last year.
CSLS's People
Name | Title | Email/Phone |
---|---|---|
1 | Executive Assistant to VP Research | Reveal Email/Phone |
2 | Executive Director, Global Accounting Operations | Reveal Email/Phone |
3 | Head Business Unit Hemophilia % Hereditary angioedema | Reveal Email/Phone |
4 | Head Global Pathogen Safety Support (GPSS), APAC | Reveal Email/Phone |
5 | Head Marketing BU Hospital und Key Account Management | Reveal Email/Phone |
6 | VP Research | Reveal Email/Phone |
7 | Head, Strategic Industry Engagement | Reveal Email/Phone |
8 | Head Communications Global Manufacturing, Health & Safety, Network Strategy, Op Excellence | Reveal Email/Phone |
9 | Head APAC Payroll | Reveal Email/Phone |
10 | Head Group Financial Control and Reporting | Reveal Email/Phone |
CSLS Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.5M | 29 | -12% | N/A | N/A |
#2 | $15.7M | 101 | 5% | N/A | N/A |
#3 | $87.9M | 405 | 25% | $292M | N/A |
#4 | $2.6M | 470 | 16% | $631.7M | N/A |
#5 | $14.9M | 96 | -8% | $81M | N/A |
#6 | $44.8M | 231 | 0% | $132.9M | N/A |
#7 | $7.6M | 49 | -37% | N/A | N/A |
#8 | $17.4M | 112 | 12% | N/A | N/A |
#9 | $334.6M | 1349 | 11% | £994.6M | N/A |
#10 | $830.2M | 5356 | 8% | N/A | N/A |
What Is CSLS?
Delivering on promises is what we do at CSL. More than a century ago, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotechnology company, that same promise has never been stronger.\n\nWe provide life-saving medicines in more than 60 nations with over 17,000 employees worldwide. CSL is driven to develop and deliver a broad range of life-saving medicines to treat disorders such as haemophilia and primary immune deficiencies, and vaccines to prevent influenza. Our therapies are also used in cardiac surgery, organ transplantation and burn treatment.\n\nInnovation has been in the DNA of CSL since our beginning in 1916 and continues as the core of everything we do today. Innovation spans our company — reflected in our 1,100 dedicated scientists who focus on solving patients’ unmet needs every day.\n\nAs a global leader, CSL collaborates and supports patient and medical communities by improving access to therapies, advancing scientific knowledge, supporting future medical researchers, and engaging our staff in the support of local communities.\nOur world-class commercial operation, combined with a large and focused R&D team and operational excellence, enable us to accurately identify, successfully develop, and dependably deliver innovations that patients and providers want.\n\nCSL has earned a reputation as a passionate yet responsible organization driven to care for patients and deliver on its commitments. Today, our future has never looked brighter.
keywords:N/AN/A
Total Funding
25475
Number of Employees
$3.9B
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CSLS News
CSL is on track to reclaim its crown as the ASX's biggest company with its share price to soar to $400 by 2025, Morgan Stanley equities...
Also on display will be the E46 M3 CSL, one of only a handful of CSLs in the U.S. It features a raft of special parts, including sophisticated...
Fans of the CSL - it stands for coupe sports leicht or "light" in German - insist it simply has no competitors. This BMW's appeal comes from...
CSL Behring Announces Global Commercialization and License Agreement with uniQure Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents exc ...
Uplifting Athletes Young Investigator Draft Presented by CSL Behring PHILADELPHIA (PRWEB) March 31, 2021 Uplifting Athletes, a nonprofit organization serving the Rare Disease Community, awarded $140,000 in medical research grants last night at its Young Investigator Draft Presented by CSL Behr ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $6614.2M | 26247 | N/A | N/A |
#2 | $5195M | 26505 | -8% | N/A |
#3 | N/A | 27899 | 11% | N/A |
#4 | $5185.9M | 28494 | 0% | N/A |
#5 | $8062.1M | 28508 | 17% | N/A |